Company profile

Valence Discovery

Drug Discovery & Development

Company profile

About Valence Discovery

Valence Labs is Recursion's AI research engine dedicated to decoding biology through advanced computational methods. The company focuses on three core pillars: Predict, Explain, and Discover. They build on over a decade of experience in perturbative biology, developing models that predict functional responses of cells to perturbations at unprecedented scale using multimodal foundation models trained on phenomics and transcriptomics datasets. Their work combines interventional data with novel methods for predicting and simulating molecular interactions to generate causal explanations for how molecular interventions shape cellular function. Using lab-in-the-loop engines of biological discovery, Valence Labs bridges functional readouts with mechanistic understanding to generate, test, and refine novel therapeutic hypotheses. The company's ambitious vision centers on creating 'virtual cells'—mechanistic models of cellular function that can accurately predict patient responses to interventions before clinical trials begin. Powered by Recursion's OS automated biology and chemistry labs generating over 60 petabytes of data, BioHive supercomputer for massive-scale computing, and a world-class interdisciplinary team, Valence Labs aims to transform drug discovery by enabling safer, more economical testing and optimization of therapeutic hypotheses through computational simulation rather than traditional experimental approaches.

Company description Valence Discovery official website

Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Valence Discovery?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

No clinical focus areas are currently listed.

Who it serves

  • Biotech
  • Pharma
  • Research

Deployment & integration

Other deployment with recorded integration context.

Geographic context

MarketsNot currently listed
Company sourceOfficial website

Company milestones

Platform expansion

Published TxPert model for predicting cellular responses to genetic perturbations (May 2025), launched OpenQDC open-source quantum datasets hub (November 2024), published Virtual Cells perspective paper (2025)

Partnerships

Recorded partners

  • Recursion (parent company)

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

BioHive

Pharmaceutical industry's leading supercomputer for AI drug discovery

Platform · OtherCompany source

OpenQDC

Open-source hub of ML-ready quantum mechanics datasets

Platform · OtherCompany source

TxPert

State-of-the-art model predicting transcriptional responses to unseen genetic perturbations

Model · OtherCompany source

Virtual Cells

Mechanistic models of cellular function that guide the discovery of novel therapeutics

Platform · OtherCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Data scale

Over 60 petabytes of data across phenomics, transcriptomics, and other modalities

Dataset coverage

40+ quantum mechanics datasets covering 1.5 billion geometries across 70 atom species

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Valence Discovery

Recent articles published on Valence Discovery's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Drug Discovery & Development

Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon